Figure 1From: Development of an in vitro model of acquired resistance to toceranib phosphate (Palladia®) in canine mast cell tumor Dose-dependent growth inhibition of parental line (C2) and three resistant sublines (TR1, TR2, TR3) after incubation with increasing concentrations of toceranib phosphate or three other KIT receptor tyrosine kinase inhibitors (LY2457546, masitinib, imatinib) for 72 hours. Back to article page